Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment</p>
Srikanta Dash, Yücel Aydın, Kyle E Widmer, et al.
Journal of Hepatocellular Carcinoma (2020) Vol. Volume 7, pp. 45-76
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Changing epidemiology of hepatocellular carcinoma in Asia
Chenhao Zhang, Yifei Cheng, Shu Zhang, et al.
Liver International (2022) Vol. 42, Iss. 9, pp. 2029-2041
Closed Access | Times Cited: 238
Inflammation-Induced Tumorigenesis and Metastasis
Sana Hibino, Tetsuro Kawazoe, Hidenori Kasahara, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5421-5421
Open Access | Times Cited: 170
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review
Amit G. Singal, Joseph K. Lim, Fasiha Kanwal
Gastroenterology (2019) Vol. 156, Iss. 8, pp. 2149-2157
Open Access | Times Cited: 106
Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC)
Pin Zhao, Samiullah Malik, Shaojun Xing
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 58
The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance
Mai-Huong Thi Ngo, Han-Yin Jeng, Yung-Che Kuo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1931-1931
Open Access | Times Cited: 57
Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
Francesco Paolo Russo, Alberto Zanetto, Elisa Pinto, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 1, pp. 500-500
Open Access | Times Cited: 56
Biological Activity of Natural and Synthetic Peptides as Anticancer Agents
Luana Vittoria Bauso, Valeria La Fauci, S. Munaò, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7264-7264
Open Access | Times Cited: 9
Unveiling the Link Between Chronic Inflammation and Cancer
Siddhant Tripathi, Yashika Sharma, Dileep Kumar
Metabolism Open (2025) Vol. 25, pp. 100347-100347
Open Access | Times Cited: 1
Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy
Elias Kouroumalis, Ioannis Tsomidis, Argyro Voumvouraki
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1166-1166
Open Access | Times Cited: 21
Uncovering the immune microenvironment and molecular subtypes of hepatitis B-related liver cirrhosis and developing stable a diagnostic differential model by machine learning and artificial neural networks
Shengke Zhang, Cheng‐Lu Jiang, Lai Jiang, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 18
Recent advances in recurrent hepatocellular carcinoma therapy
Yuxue Gao, Qi-Qi Ning, Pengxiang Yang, et al.
World Journal of Hepatology (2023) Vol. 15, Iss. 4, pp. 460-476
Open Access | Times Cited: 17
NLRP3 Inflammasome in Acute and Chronic Liver Diseases
Katia Sayaf, Sara Battistella, Francesco Paolo Russo
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4537-4537
Open Access | Times Cited: 6
Prefoldin Function in Cellular Protein Homeostasis and Human Diseases
İsmail Tahmaz, Somayeh Shahmoradi Ghahe, Ulrike Topf
Frontiers in Cell and Developmental Biology (2022) Vol. 9
Open Access | Times Cited: 27
Resistance‐Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC‐CANUHC Analysis
Himain Perera, Haris Imsirovic, Gisela Macphail, et al.
Journal of Viral Hepatitis (2025) Vol. 32, Iss. 2
Closed Access
Dynamic Prediction of the Risk of Hepatocellular Carcinoma After DAA Treatment for Hepatitis C Patients
Xinyan Ma, Lili Huang, Meijie Yu, et al.
Cancer Control (2025) Vol. 32
Open Access
Fibrosis reversal after hepatitis C virus elimination
Don C. Rockey
Current Opinion in Gastroenterology (2019) Vol. 35, Iss. 3, pp. 137-144
Open Access | Times Cited: 40
Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection
Arpan Mohanty, Sarah Salameh, Adeel A. Butt
Current HIV/AIDS Reports (2019) Vol. 16, Iss. 5, pp. 389-394
Closed Access | Times Cited: 40
Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection
Mohammed El‐Mowafy, Abdelaziz Elgaml, Mohamed El‐Mesery, et al.
Biology (2021) Vol. 10, Iss. 1, pp. 55-55
Open Access | Times Cited: 30
Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Hrvoje Roguljić, Vjera Ninčević, Kristina Bojanić, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 28
Deubiquitination and Activation of the NLRP3 Inflammasome by UCHL5 in HCV-Infected Cells
Akshaya Ramachandran, Binod Kumar, Gulam Waris, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick
Haili Wang, Yuhang Zhang, Jingming Zhou, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 20
Role of infectious agents in Cancer pathogenesis and therapy
Ezichi F. Ofoezie, C Ogbonna, Sandra C. Olisakwe, et al.
The Microbe (2025), pp. 100284-100284
Open Access
Acute COVID-19 and LongCOVID syndrome – molecular implications for therapeutic strategies - review
Katarzyna Michalak, Alicja Michalak, Alicja Brenk-Krakowska
Frontiers in Immunology (2025) Vol. 16
Open Access
Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis
Tom Domovitz, Meital Gal-Tanamy
Journal of Clinical Medicine (2021) Vol. 10, Iss. 3, pp. 551-551
Open Access | Times Cited: 25
Potential of antiviral drug oseltamivir for the treatment of liver cancer
Pei‐Ju Huang, Chun‐Ching Chiu, Min-Hua Hsiao, et al.
International Journal of Oncology (2021) Vol. 59, Iss. 6
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top